close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Warrant (NQ:SABSW)

0.0337 -0.0036 (-9.65%)
Streaming Delayed Price Updated: 9:44 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Warrant

< Previous 1 2 3 Next >
News headline image
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Provides SAB-142 Trial Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at INNODIA Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Executive Leadership Change
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
SAB also announces closing of $7.5 million financing, the first tranche of $130 million private placement 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants of SARS-CoV-2 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today